Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

AI lung nodules detection in contextflow and Lung-RADS in mint Lesion

Leverage Advanced AI-Driven Nodule Detection and Analysis for Comprehensive Patient Care

Discover the power of streamlined AI-driven lung screening with contextflow ADVANCE Chest CT integrated into mint Lesion. With automated lung nodule detection and segmentation, contextflow highlights findings directly within the mint Lesion platform, where users can seamlessly review, customize or add findings.

mint Lesion supports the Lung-RADS 2022 guidelines, featuring built-in automated scoring to enhance accuracy and consistency in lung nodule evaluation. For high-risk patients, contextflow ADVANCE Chest CT extends its capabilities beyond nodules, assisting in the analysis of COPD and *coming soon* identifying calcifications in coronary vessels, equipping users with deeper insights for comprehensive care.

Explore how the innovative solution is going to be integrated into the cutting-edge deepcOS® AIR® ecosystem. Check out this brief video on Youtube to see it in action.

 

Related Resources

Related Resources

Creating evidence to tackle COVID-19

Our COVID-19 reading template is in use for two weeks, and its usage is multiplying. We are grateful for the close cooperation and feedback from…

Potential of using structured data from clinical trials and routine for AI and radiomics research

Dr. Nils Grosse Hokamp shares his experience of using mint Lesion™ at the University Hospital Cologne in this brief interview. He talks about how they…

Mint Medical provides a reading template for the standardized assessment and documentation of COVID-19 disease (coronavirus) based on CT imaging

In the first week of March, we will make the relevant software functions available for all our current users at no cost. We plan to offer the COVID-19…